It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chronic suppurative otitis media (CSOM) is a widespread, debilitating problem with poorly understood immunology. Here, we assess the host response to middle ear infection over the course of a month post-infection in a mouse model of CSOM and in human subjects with the disease. Using multiparameter flow cytometry and a binomial generalized linear machine learning model, we identified Ly6G, a surface marker of mature neutrophils, as the most informative factor of host response driving disease in the CSOM mouse model. Consistent with this, neutrophils were the most abundant cell type in infected mice and Ly6G expression tracked with the course of infection. Moreover, neutrophil-specific immunomodulatory treatment using the neutrophil elastase inhibitor GW 311616A significantly reduces bacterial burden relative to ofloxacin-only treated animals in this model. The levels of dsDNA in middle ear effusion samples are elevated in both humans and mice with CSOM and decreased during treatment, suggesting that dsDNA may serve as a molecular biomarker of treatment response. Together these data strongly implicate neutrophils in the ineffective immune response to P. aeruginosa infection in CSOM and suggest that immunomodulatory strategies may benefit drug-tolerant infections for chronic biofilm-mediated disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Stanford University, Department of Otolaryngology, Head and Neck Surgery, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
2 University of Chicago, Department of Medicine, Section of Computational Biomedicine and Biomedical Data Science, Chicago, USA (GRID:grid.170205.1) (ISNI:0000 0004 1936 7822)
3 Tehran University of Medical Sciences, Department of Otolaryngology, Head and Neck Surgery, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922)
4 Stanford University, Department of Medicine, Infectious Diseases, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
5 University of Otago, Department of Microbiology and Immunology, Dunedin, New Zealand (GRID:grid.29980.3a) (ISNI:0000 0004 1936 7830)